Assembling OX40 Aptamers on a Molecular Scaffold to Create a Receptor-Activating Aptamer

This publication has 32 references indexed in Scilit:

• Sequence- and target-independent angiogenesis suppression by siRNA via TLR3
  Nature, 2008
• Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice
  Journal of Clinical Investigation, 2008
• Pegaptanib 1-Year Systemic Safety Results from a Safety–Pharmacokinetic Trial in Patients with Neovascular Age-Related Macular Degeneration
  Ophthalmology, 2007
• Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain
  Molecular Immunology, 2007
• Immunostimulatory monoclonal antibodies for cancer therapy
  Nature Reviews Cancer, 2007
• First-in-Human Experience of an Antidote-Controlled Anticoagulant Using RNA Aptamer Technology
  Circulation, 2006
• Anti-OX40 (CD134) Administration to Nonhuman Primates: Immunostimulatory Effects and Toxicokinetic Study
  Journal of Immunotherapy, 2006
• H1 RNA polymerase III promoter-driven expression of an RNA aptamer leads to high-level inhibition of intracellular protein activity
  Nucleic Acids Research, 2006
• Anti-tumour therapeutic efficacy of OX40L in murine tumour model
  Vaccine, 2004
• Anti‐metastatic vaccination of tumor‐bearing mice with il‐2‐gene‐inserted tumor cells
  International Journal of Cancer, 1993